UBS Global Healthcare Conference - BIO-RAD LABORATORIES INC

Explicit Guidance:

• Operating Margin: Targeting mid-teens (approx. 16-19%) within the next two years, viewed as a milestone en route to further expansion.
• Cost Savings: Targeting $30–$35 million in net annual savings, with benefits starting to ramp in 2027 and fully realized by 2028.
• Free Cash Flow (FCF): Maintaining full-year range of $290–$340 million; expects 2028 to see further FCF expansion through margin improvements and working capital efficiencies.
• FY2024 Q4 Outlook: Guidance assumes continuity of Q3 conditions with no notable market improvement; headwinds expected to persist into 2027.
• Process Chromatography Growth: Aims to return to growth in 2027, targeting mid-single-digit long-term growth, evolving to high single digits as clinical programs migrate to commercial.
• Digital PCR (ddPCR): Aims for mid-single-digit sustainable long-term growth, driven by instrument sales and eventual consumable pull-through (expected to normalize over 6–12 months, potentially accelerating in 2027+).

Business-Segment Outlook:

• Tools (Life Sciences): Focused on achieving mid-single-digit growth across the portfolio via new product introductions and improved execution.
• Diagnostics: Identifying lifecycle evolution opportunities; seeking M&A to strengthen molecular and growth areas, potentially tucking in assets to close portfolio gaps in quality controls (e.g., oncology).
• Clinical ddPCR: Recognized as a future growth vector; anticipating traction in commercial diagnostics over the coming years, leveraging partnerships (e.g., Genoscopy) for market validation rather than direct entry.
• China Strategy: Manufacturing capacity for specific SKUs added in Q1 to enable participation in government tenders; views the region as volatile but committed to growth in tools and chromatography.
• R&D Vitality: Accelerating software development and AI integration (e.g., image analysis in Western blot); prioritizing internal productivity gains across finance, commercial, and R&D functions.
• M&A: Shifting strategy to focus on assets with existing market positions to accelerate top-line growth and margin expansion; approach is product-agnostic (Tools or Diagnostics).

Market and Competitive Outlook:

• Demand Trends: Large Pharma/Bioprocessing viewed as the strongest end market; funding expected to cascade from late-stage commercial to the discovery stage where Bio-Rad is positioned.
• Consumer/Research Sentiment: A&G sector showing mixed sentiment; US depends on NIH budget outcomes; Europe faces budget shifts toward defense; China driven by desire to normalize research activity.
• Pricing & Mix: Gross margin expansion expected via mix evolution (e.g., strong margins on QX700 instruments) and execution improvements; competitive wins in ddPCR instruments validated despite A&G softness.
• Supply Chain: Improved execution in inventory management and order timing; local manufacturing in China to secure government tender participation.

Macro / Industry Outlook:

• End Markets: Biopharma funding levels described as strong (doubling YoY previously), but timing of spend trickle-down to discovery-stage customers is a key variable.
• Geopolitical/Regulatory: China market growth expected to be volatile; government policy changes unrelated to company execution previously impacted vaccine-related resin demand.
• Economic Environment: Headwinds anticipated to persist through 2027; management notes that calendar changes do not automatically resolve market conditions.

Strategic Initiatives:

• AI Integration: Expanding AI usage in internal productivity (supply chain, R&D, finance) and product capabilities (image analysis); viewing AI as critical for workflow efficiency and research productivity.
• Restructuring: Recent restructuring charges larger than projected net savings; intended to fund capability building to support strategic execution while targeting long-term efficiency.
• Manufacturing Expansion: Completed China manufacturing setup in Q1 to enable participation in local government tenders.
• Sartorius Stake: Maintained as a "monetizable asset" on the balance sheet; provides optionality for future M&A but not relied upon for day-to-day operational growth.
• Capital Allocation: Strong alignment with investor base (including Elliott) on execution and capital priorities; prioritizing organic growth and accretive M&A over transformative deals.

Risks and Headwinds to Outlook:

• Consumable Pull-Through: ddPCR instrument sales (up >20% QoQ) outpace consumable revenue; normalization expected to take 6–12 months due to market softness.
• Market Volatility: China growth is volatile; A&G sentiment remains mixed pending budget clarity.
• Execution Risk: Transition from negative/declining growth to market growth rates requires successful portfolio evolution and R&D timing; no "silver bullet" exists for immediate turnaround.
• Historical M&A Performance: Acknowledged that past M&A deals were a drag; new strategy aims to mitigate this through more rigorous asset selection.
• Macro Persistence: Headwinds expected to carry into 2027, limiting near-term acceleration.

Management Tone on the Future:

• Confidence Level: Cautiously optimistic; emphasizes "foundational" progress and "building blocks" rather than immediate transformation.
• Time Horizon: Views current growth trajectory as a multi-year journey; expects tangible financial impact (margins, FCF) to materialize more fully by 2027–2028.
• Execution Focus: Strong emphasis on "predictable execution" and internal self-help (cost management, R&D vitality) as the primary drivers, with M&A acting as an accelerator.
• Sentiment: Describes the current environment as "early" in the recovery arc; acknowledges volatility but highlights specific areas (Biopharma, China manufacturing, ddPCR) showing positive traction.